Company intelligence / Profile preview

Strongbridge Biopharma

Trevose, Pennsylvania, United Statesxerispharma.com ↗

Ownership: Public · SBBP
Employees: ~65
Development stage: Commercial

Overview

Strongbridge commercialized KEVEYIS® (dichlorphenamide) for primary periodic paralysis and advanced RECORLEV® (levoketoconazole) for endogenous Cushing’s syndrome through successful Phase 3 trials and NDA submission. Recorlev showed normalization of cortisol in ~30% of patients after six months in pivotal studies. Veldoreotide was in preclinical/early clinical development for acromegaly[8].

Therapeutic areas: EndocrinologyCardiovascularRare Diseases
Modalities: Small moleculessynthetic peptides[6]
Industry: Biotech

Drug pipeline

3 assets

dichlorphenamide

Commercial

Indications: Primary Periodic Paralysis

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $0
Total revenue: $10M
Enterprise value: $-45.6M

Beyond the preview

Go deeper on Strongbridge Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Strongbridge Biopharma.

Explore the full profile